G22恒峰集团

Global
关于G22恒峰集团

致力于纳米抗体
创新药物研发

关于G22恒峰集团
科研论文
截止现在，G22恒峰集团生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
2024-12-03
Efficient development of nanobody-based affinity chromatography for AAV8 purification.
发表于:Protein Expression and Purification
查看更多内容
2024-10-30
Ce-MOF@Au-Based Electrochemical Immunosensor for Apolipoprotein A1 Detection Using Nanobody Technology.
发表于:ACS Applied Materials & Interfaces
查看更多内容
2024-06-11
A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma.
发表于:J Allergy Clin Immunol.
查看更多内容
2024-06-10
Nanobody-Based Microfluidic Immunosensor Chip Using Tetraphenylethylene-Derived Covalent Organic Frameworks as Aggregation-Induced Electrochemiluminescence Emitters for the Detection of Thymic Stromal Lymphopoietin.
发表于:Analytical Chemistry
查看更多内容
2024-05-16
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
发表于:Journal of Nanobiotechnology.
查看更多内容
2024-02-16
High performance production process development and scale-up of ananti-TSLP nanobody
发表于:Protein expression and purification, 218, 106441.
查看更多内容
总计 24 1234